Please select the eligibility criteria that correspond to the clinical trial below.
Title: Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia
Brief Summary: The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia


Options:
A: Men and women with early carotid atherosclerosis and moderately elevated LDL cholesterol between the 60th and 90th percentiles.
B: Inclusion Criteria:

* BMI over 40
* Gastric banding or gastric bypass

Exclusion Criteria:

* Renal insufficiency
* Thrombopenia
* Long term anticoagulant treatment
* Pregnancy
* Allergy to heparin
C: Inclusion Criteria:

* Diagnosis of mixed hyperlipidemia
* At least 18 years of age

Exclusion Criteria:

* Women who are pregnant or lactating, or planning to become pregnant.
* Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)
* Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
* Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study
D: Inclusion Criteria:

* Written informed consent.
* Age\>18 years old.
* Negative serum pregnancy test (in women of childbearing only).
* Patients submitted to endovascular procedures below-the-knee by not exclusively.
* Patient understands and is willing and able to comply with the study instructions and follow-up visit.
* More than 70% stenosis or occlusion of the three distal arteries including or not the tibiofibular trunk (TFT).
* Tissue loss (Rutherford 5).
* One or more patent vessel of pedal arch.

Exclusion Criteria:

* TASC II D femoral and/or popliteal occlusion.
* Life expectancy less than 1 year.
* Allergy or contraindication to apixaban treatment.
* Allergy or contraindication to dual antiplatelet treatment.
* Creatinine clearance less than 30mL/min.
* Planned major amputation before procedure.
* Hybrid procedure (open and endovascular).
* Use of fibrinolytic in the past 10 days.
* Known HIV infection.
* Liver disease (acute or chronic hepatitis and cirrhosis).
* Drug addiction or alcohol abuse 12 months before the randomization.
* Concomitant medications thatinhibit the CYP 3A4 cytochrome and P glycoprotein (ketoconazole, Iitraconazole, ritonavir).
* Platelets count inferior to 100x109/L.
* INR more than 1.5.
* History or condition with high risk of bleeding: Eg. Trauma within 30 days before randomization, gastrointestinal bleeding 6 month before the randomization, intra-ocular, spinal, intra-articular bleeding (any time before), AV malformation, cerebral aneurysm and hypertension without control.

Answer: C